Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42


APRIL:TACI axis is dispensable for the immune response to rabies vaccination.

Haley SL, Tzvetkov EP, Lytle AG, Alugupalli KR, Plummer JR, McGettigan JP.

Antiviral Res. 2017 Aug;144:130-137. doi: 10.1016/j.antiviral.2017.06.004. Epub 2017 Jun 12.


Targeting Vaccine-Induced Extrafollicular Pathway of B Cell Differentiation Improves Rabies Postexposure Prophylaxis.

Haley SL, Tzvetkov EP, Meuwissen S, Plummer JR, McGettigan JP.

J Virol. 2017 Mar 29;91(8). pii: e02435-16. doi: 10.1128/JVI.02435-16. Print 2017 Apr 15.


A Bivalent, Chimeric Rabies Virus Expressing Simian Immunodeficiency Virus Envelope Induces Multifunctional Antibody Responses.

Dunkel A, Shen S, LaBranche CC, Montefiori D, McGettigan JP.

AIDS Res Hum Retroviruses. 2015 Nov;31(11):1126-38. doi: 10.1089/AID.2014.0319. Epub 2015 May 5.


Lymph node but not intradermal injection site macrophages are critical for germinal center formation and antibody responses to rabies vaccination.

Lytle AG, Shen S, McGettigan JP.

J Virol. 2015 Mar;89(5):2842-8. doi: 10.1128/JVI.03409-14. Epub 2014 Dec 24.


Safety and serological response to a matrix gene-deleted rabies virus-based vaccine vector in dogs.

McGettigan JP, David F, Figueiredo MD, Minke J, Mebatsion T, Schnell MJ.

Vaccine. 2014 Mar 26;32(15):1716-9. doi: 10.1016/j.vaccine.2014.01.043. Epub 2014 Feb 7.


ICAM-1-based rabies virus vaccine shows increased infection and activation of primary murine B cells in vitro and enhanced antibody titers in-vivo.

Norton JE Jr, Lytle AG, Shen S, Tzvetkov EP, Dorfmeier CL, McGettigan JP.

PLoS One. 2014 Jan 29;9(1):e87098. doi: 10.1371/journal.pone.0087098. eCollection 2014.


Comparison of Heterologous Prime-Boost Strategies against Human Immunodeficiency Virus Type 1 Gag Using Negative Stranded RNA Viruses.

Lawrence TM, Wanjalla CN, Gomme EA, Wirblich C, Gatt A, Carnero E, GarcĂ­a-Sastre A, Lyles DS, McGettigan JP, Schnell MJ.

PLoS One. 2013 Jun 26;8(6):e67123. doi: 10.1371/journal.pone.0067123. Print 2013.


Reinvestigating the role of IgM in rabies virus postexposure vaccination.

Dorfmeier CL, Shen S, Tzvetkov EP, McGettigan JP.

J Virol. 2013 Aug;87(16):9217-22. doi: 10.1128/JVI.00995-13. Epub 2013 Jun 12.


B cell infection and activation by rabies virus-based vaccines.

Lytle AG, Norton JE Jr, Dorfmeier CL, Shen S, McGettigan JP.

J Virol. 2013 Aug;87(16):9097-110. doi: 10.1128/JVI.00800-13. Epub 2013 Jun 12.


Investigating the role for IL-21 in rabies virus vaccine-induced immunity.

Dorfmeier CL, Tzvetkov EP, Gatt A, McGettigan JP.

PLoS Negl Trop Dis. 2013;7(3):e2129. doi: 10.1371/journal.pntd.0002129. Epub 2013 Mar 14.


Protective vaccine-induced CD4(+) T cell-independent B cell responses against rabies infection.

Dorfmeier CL, Lytle AG, Dunkel AL, Gatt A, McGettigan JP.

J Virol. 2012 Nov;86(21):11533-40. doi: 10.1128/JVI.00615-12. Epub 2012 Aug 15.


Experimental rabies vaccines for humans.

McGettigan JP.

Expert Rev Vaccines. 2010 Oct;9(10):1177-86. doi: 10.1586/erv.10.105. Review.


Characterization of a single-cycle rabies virus-based vaccine vector.

Gomme EA, Faul EJ, Flomenberg P, McGettigan JP, Schnell MJ.

J Virol. 2010 Mar;84(6):2820-31. doi: 10.1128/JVI.01870-09. Epub 2010 Jan 6.


The cell biology of rabies virus: using stealth to reach the brain.

Schnell MJ, McGettigan JP, Wirblich C, Papaneri A.

Nat Rev Microbiol. 2010 Jan;8(1):51-61. doi: 10.1038/nrmicro2260. Review.


Rabies virus-based vaccines elicit neutralizing antibodies, poly-functional CD8+ T cell, and protect rhesus macaques from AIDS-like disease after SIV(mac251) challenge.

Faul EJ, Aye PP, Papaneri AB, Pahar B, McGettigan JP, Schiro F, Chervoneva I, Montefiori DC, Lackner AA, Schnell MJ.

Vaccine. 2009 Dec 11;28(2):299-308. doi: 10.1016/j.vaccine.2009.10.051. Epub 2009 Oct 29.


Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates.

Cenna J, Hunter M, Tan GS, Papaneri AB, Ribka EP, Schnell MJ, Marx PA, McGettigan JP.

J Infect Dis. 2009 Oct 15;200(8):1251-60. doi: 10.1086/605949.


Interferon-beta expressed by a rabies virus-based HIV-1 vaccine vector serves as a molecular adjuvant and decreases pathogenicity.

Faul EJ, Wanjalla CN, McGettigan JP, Schnell MJ.

Virology. 2008 Dec 20;382(2):226-38. doi: 10.1016/j.virol.2008.09.019. Epub 2008 Oct 21.


Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene.

Cenna J, Tan GS, Papaneri AB, Dietzschold B, Schnell MJ, McGettigan JP.

Vaccine. 2008 Nov 25;26(50):6405-14. doi: 10.1016/j.vaccine.2008.08.069. Epub 2008 Sep 18.


Highly attenuated rabies virus-based vaccine vectors expressing simian-human immunodeficiency virus89.6P Env and simian immunodeficiency virusmac239 Gag are safe in rhesus macaques and protect from an AIDS-like disease.

McKenna PM, Koser ML, Carlson KR, Montefiori DC, Letvin NL, Papaneri AB, Pomerantz RJ, Dietzschold B, Silvera P, McGettigan JP, Schnell MJ.

J Infect Dis. 2007 Apr 1;195(7):980-8. Epub 2007 Feb 20.


A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice.

Li J, Faber M, Papaneri A, Faber ML, McGettigan JP, Schnell MJ, Dietzschold B.

Virology. 2006 Dec 5-20;356(1-2):147-54. Epub 2006 Aug 30.


Rabies virus glycoprotein as a carrier for anthrax protective antigen.

Smith ME, Koser M, Xiao S, Siler C, McGettigan JP, Calkins C, Pomerantz RJ, Dietzschold B, Schnell MJ.

Virology. 2006 Sep 30;353(2):344-56. Epub 2006 Jul 3.


siRNA targeting vaccinia virus double-stranded RNA binding protein [E3L] exerts potent antiviral effects.

Dave RS, McGettigan JP, Qureshi T, Schnell MJ, Nunnari G, Pomerantz RJ.

Virology. 2006 May 10;348(2):489-97. Epub 2006 Feb 9.


Enhanced humoral HIV-1-specific immune responses generated from recombinant rhabdoviral-based vaccine vectors co-expressing HIV-1 proteins and IL-2.

McGettigan JP, Koser ML, McKenna PM, Smith ME, Marvin JM, Eisenlohr LC, Dietzschold B, Schnell MJ.

Virology. 2006 Jan 20;344(2):363-77. Epub 2005 Oct 14.


Strong cellular and humoral anti-HIV Env immune responses induced by a heterologous rhabdoviral prime-boost approach.

Tan GS, McKenna PM, Koser ML, McLinden R, Kim JH, McGettigan JP, Schnell MJ.

Virology. 2005 Jan 5;331(1):82-93.


Rabies virus nucleoprotein as a carrier for foreign antigens.

Koser ML, McGettigan JP, Tan GS, Smith ME, Koprowski H, Dietzschold B, Schnell MJ.

Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9405-10. Epub 2004 Jun 14.


Recombinant rhabdoviruses as potential vaccines for HIV-1 and other diseases.

McKenna PM, McGettigan JP, Pomerantz RJ, Dietzschold B, Schnell MJ.

Curr HIV Res. 2003 Apr;1(2):229-37. Review.


Budding of PPxY-containing rhabdoviruses is not dependent on host proteins TGS101 and VPS4A.

Irie T, Licata JM, McGettigan JP, Schnell MJ, Harty RN.

J Virol. 2004 Mar;78(6):2657-65. Erratum in: J Virol. 2004 May;78(10):5532.


Second-generation rabies virus-based vaccine vectors expressing human immunodeficiency virus type 1 gag have greatly reduced pathogenicity but are highly immunogenic.

McGettigan JP, Pomerantz RJ, Siler CA, McKenna PM, Foley HD, Dietzschold B, Schnell MJ.

J Virol. 2003 Jan;77(1):237-44.


HIV-1 vaccines: the search continues.

McGettigan JP, McKenna PM, Schnell MJ.

Clin Lab Med. 2002 Sep;22(3):799-820, viii. Review.


Overexpression of the rabies virus glycoprotein results in enhancement of apoptosis and antiviral immune response.

Faber M, Pulmanausahakul R, Hodawadekar SS, Spitsin S, McGettigan JP, Schnell MJ, Dietzschold B.

J Virol. 2002 Apr;76(7):3374-81.


Live and killed rhabdovirus-based vectors as potential hepatitis C vaccines.

Siler CA, McGettigan JP, Dietzschold B, Herrine SK, Dubuisson J, Pomerantz RJ, Schnell MJ.

Virology. 2002 Jan 5;292(1):24-34.


Rhabdoviruses and the cellular ubiquitin-proteasome system: a budding interaction.

Harty RN, Brown ME, McGettigan JP, Wang G, Jayakar HR, Huibregtse JM, Whitt MA, Schnell MJ.

J Virol. 2001 Nov;75(22):10623-9.


Genetic engineering of live rabies vaccines.

Morimoto K, McGettigan JP, Foley HD, Hooper DC, Dietzschold B, Schnell MJ.

Vaccine. 2001 May 14;19(25-26):3543-51.


High level expression of a human rabies virus-neutralizing monoclonal antibody by a rhabdovirus-based vector.

Morimoto K, Schnell MJ, Pulmanausahakul R, McGettigan JP, Foley HD, Faber M, Hooper DC, Dietzschold B.

J Immunol Methods. 2001 Jun 1;252(1-2):199-206.


A recombinant rabies virus expressing vesicular stomatitis virus glycoprotein fails to protect against rabies virus infection.

Foley HD, McGettigan JP, Siler CA, Dietzschold B, Schnell MJ.

Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14680-5.


Reinvestigation of the role of the rabies virus glycoprotein in viral pathogenesis using a reverse genetics approach.

Morimoto K, Foley HD, McGettigan JP, Schnell MJ, Dietzschold B.

J Neurovirol. 2000 Oct;6(5):373-81.


Recombinant rabies virus as potential live-viral vaccines for HIV-1.

Schnell MJ, Foley HD, Siler CA, McGettigan JP, Dietzschold B, Pomerantz RJ.

Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3544-9.

Supplemental Content

Loading ...
Support Center